Tetrahydrobenzazepine derivatives which inhibit lipoxygenase
AssigneePfizer Inc.
InventorsYoko Hoshino, Takafumi Ikeda
Life of this patent
Estimating the term…
Loading patent…
AssigneePfizer Inc.
InventorsYoko Hoshino, Takafumi Ikeda
Estimating the term…
Compounds of the formula ##STR1## wherein n is 1 to 5 and R is hydrogen, C.sub.1 to C.sub.4 alkyl, arylalkyl having from one to four carbon atoms in the alkyl moiety or arylalkyl substituted with one or more substituents selected independently from the group consisting of halogen, nitro, cyano, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkoxy, C.sub.1 to C.sub.6 halosubstituted alkyl, C.sub.1 to C.sub.6 hydroxysubstituted alkyl, C.sub.2 to C.sub.7 alkoxycarbonyl and aminocarbonyl, and the pharmaceutically acceptable salts thereof, inhibit the enzyme lipoxygenase and are useful in treating allergy and inflammatory and cardiovascular conditions for which the action of lipoxygenase has been implicated. These compounds form the active ingredient in pharmaceutical compositions for treating such conditions.
A compound of the formula ##STR8## or a pharmaceutically acceptable salt thereof, wherein:
A method of treating allergy or inflammatory or cardiovascular conditions in a mammal comprising administering to said mammal a lipoxygenase-inhibiting amount of a compound according to claim I or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.